Physician profile

Marie Bittner

Adult Health (Nurse Practitioner) · Park Ridge, IL

NPI 1134773385

$792.02

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$17.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $256.97 2021
Novo Nordisk INC $115.93 2021
Lilly USA, LLC $105.06 2021
Janssen Pharmaceuticals, INC $95.03 2021
Eisai INC. $78.14 2021
Amgen INC. $71.99 2021
Phadia US INC. $19.62 2022
Boston Scientific Corporation $17.89 2023 Advantage System
Paratek Pharmaceuticals, INC. $17.25 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.14 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marie Bittner

$792.02

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/10796151/marie-bittner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.